Guilherme Jorge Costa1, Maria Júlia Gonçalves de Mello2, Carlos Gil Ferreira3, Luiz Claudio Santos Thuler4. 1. Department of Oncology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil. 2. Hospital Infection Control Committee, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil. 3. Brazilian Ministry of Health, National Clinical Cancer Research Network (RNPCC), Rio de Janeiro, RJ, Brazil. 4. Clinical Research Division, Brazilian National Cancer Institute (INCA), Rua André Cavalcanti, 37, 2° andar, Rio de Janeiro, RJ, 20231-050, Brazil. lthuler@gmail.com.
Abstract
PURPOSE: Elderly patients with lung cancer tend to be undertreated in comparison to younger patients. The objective of this study is to compare treatment modalities offered to lung cancer patients from 70 years of age or more with patients under 70. METHODS: For this study, an analytical cross-sectional epidemiological study conducted with data from the Brazilian hospital-based cancer registries between the years 2000 and 2011. In addition, odds ratios (OR) were calculated, with a 95% confidence intervals (95% CI), in conjunction with the construction of a logistic regression model. RESULTS: By analyzing the records of 40,403 patients with lung cancer, we found that overall, patients from 70 years of age or more corresponded to 28.6% of the study population. Squamous cell carcinoma was the most common histological type among patients ≥70 years of age, whereas adenocarcinoma was the more prevalent type among younger patients. In comparison to younger patients, the older ones were treated less often (OR = 0.57; 95% CI: 0.52-0.62). Moreover, older patients were less likely to undergo surgery (OR = 0.69; 95% CI: 0.64-0.75), radiotherapy (OR = 0.86; 95% CI: 0.81-0.92), chemotherapy (OR = 0.61; 95% CI: 0.57-0.64), or an association of two or more treatment modalities (OR = 0.58; 95% CI: 0.54-0.62). CONCLUSION: The study finds that Brazilian lung cancer patients ≥70 years of age are often undertreated and higher percentage of early death rates as compared to patients under 70. In regard to treatment, age alone should not determine whether patients with lung cancer are treated or not.
PURPOSE: Elderly patients with lung cancer tend to be undertreated in comparison to younger patients. The objective of this study is to compare treatment modalities offered to lung cancerpatients from 70 years of age or more with patients under 70. METHODS: For this study, an analytical cross-sectional epidemiological study conducted with data from the Brazilian hospital-based cancer registries between the years 2000 and 2011. In addition, odds ratios (OR) were calculated, with a 95% confidence intervals (95% CI), in conjunction with the construction of a logistic regression model. RESULTS: By analyzing the records of 40,403 patients with lung cancer, we found that overall, patients from 70 years of age or more corresponded to 28.6% of the study population. Squamous cell carcinoma was the most common histological type among patients ≥70 years of age, whereas adenocarcinoma was the more prevalent type among younger patients. In comparison to younger patients, the older ones were treated less often (OR = 0.57; 95% CI: 0.52-0.62). Moreover, older patients were less likely to undergo surgery (OR = 0.69; 95% CI: 0.64-0.75), radiotherapy (OR = 0.86; 95% CI: 0.81-0.92), chemotherapy (OR = 0.61; 95% CI: 0.57-0.64), or an association of two or more treatment modalities (OR = 0.58; 95% CI: 0.54-0.62). CONCLUSION: The study finds that Brazilian lung cancerpatients ≥70 years of age are often undertreated and higher percentage of early death rates as compared to patients under 70. In regard to treatment, age alone should not determine whether patients with lung cancer are treated or not.
Authors: A G Pallis; C Gridelli; U Wedding; C Faivre-Finn; G Veronesi; M Jaklitsch; A Luciani; M O'Brien Journal: Ann Oncol Date: 2014-03-16 Impact factor: 32.976
Authors: Sunny Wang; Melisa L Wong; Nathan Hamilton; J Ben Davoren; Thierry M Jahan; Louise C Walter Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544
Authors: Cesare Gridelli; Paolo Maione; Antonio Rossi; Giovanni Palazzolo; Giuseppe Colantuoni; Emanuela Rossi Journal: Cancer Treat Rev Date: 2009-05-19 Impact factor: 12.111
Authors: Luiz Claudio Santos Thuler; Guilherme Jorge Costa; Maria Júlia Gonçalves de Mello; Carlos Gil Ferreira Journal: J Cancer Res Clin Oncol Date: 2017-09-05 Impact factor: 4.553
Authors: Clark DuMontier; Kah Poh Loh; Paul A Bain; Rebecca A Silliman; Tammy Hshieh; Gregory A Abel; Benjamin Djulbegovic; Jane A Driver; William Dale Journal: J Clin Oncol Date: 2020-04-06 Impact factor: 50.717
Authors: Coeli Regina Carneiro Ximenes; Anke Bergmann; Jurema Telles de Oliveira Lima; Wigna Rayssa Pereira Lima; Murilo Carlos de Britto; Maria Júlia Gonçalves de Mello; Luiz Claudio Santos Thuler Journal: J Patient Exp Date: 2020-02-27
Authors: Vincent Vinh-Hung; Olena Gorobets; Andre Duerinkcx; Suresh Dutta; Eromosele Oboite; Joan Oboite; Ahmed Ali; Thandeka Mazibuko; Ulf Karlsson; Alexander Chi; David Lehrman; Omer Hashim Mohammed; Mohammad Mohammadianpanah; Gokoulakrichenane Loganadane; Natalia Migliore; Maria Vasileiou; Nam P Nguyen; Huan Giap Journal: Transl Cancer Res Date: 2022-09 Impact factor: 0.496